Cell-to-cell heterogeneity of EWSR1-FLI1 activity determines proliferation/migration choices in Ewing sarcoma cells

[1]  Ben Lehner,et al.  Maternal age generates phenotypic variation in C. elegans , 2017, Nature.

[2]  R. Linding,et al.  The hypoxic cancer secretome induces pre-metastatic bone lesions through lysyl oxidase , 2015, Nature.

[3]  P. Sorensen,et al.  Translational Activation of HIF1α by YB-1 Promotes Sarcoma Metastasis. , 2015, Cancer cell.

[4]  A. Llombart‐Bosch,et al.  Suppression of deacetylase SIRT1 mediates tumor-suppressive NOTCH response and offers a novel treatment option in metastatic Ewing sarcoma. , 2014, Cancer research.

[5]  M. Beckerle,et al.  Molecular dissection of the mechanism by which EWS/FLI expression compromises actin cytoskeletal integrity and cell adhesion in Ewing sarcoma , 2014, Molecular biology of the cell.

[6]  Li Ding,et al.  Genomic landscape of Ewing sarcoma defines an aggressive subtype with co-association of STAG2 and TP53 mutations. , 2014, Cancer discovery.

[7]  A. McKenna,et al.  The genomic landscape of pediatric Ewing sarcoma. , 2014, Cancer discovery.

[8]  U. Dirksen,et al.  Cyclophosphamide compared with ifosfamide in consolidation treatment of standard-risk Ewing sarcoma: results of the randomized noninferiority Euro-EWING99-R1 trial. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  H. Spaink,et al.  Ewing sarcoma inhibition by disruption of EWSR1–FLI1 transcriptional activity and reactivation of p53 , 2014, The Journal of pathology.

[10]  Jun S. Wei,et al.  The Genomic Landscape of the Ewing Sarcoma Family of Tumors Reveals Recurrent STAG2 Mutation , 2014, PLoS genetics.

[11]  Dafydd G. Thomas,et al.  Stress-Induced CXCR4 Promotes Migration and Invasion of Ewing Sarcoma , 2014, Molecular Cancer Research.

[12]  Elizabeth T. Wiles,et al.  ZEB2 Represses the Epithelial Phenotype and Facilitates Metastasis in Ewing Sarcoma. , 2013, Genes & cancer.

[13]  J. Olivo-Marin,et al.  αTAT1 catalyses microtubule acetylation at clathrin-coated pits , 2013, Nature.

[14]  Corbin E. Meacham,et al.  Tumour heterogeneity and cancer cell plasticity , 2013, Nature.

[15]  M. Stern,et al.  MiR-30a-5p connects EWS-FLI1 and CD99, two major therapeutic targets in Ewing tumor , 2013, Oncogene.

[16]  Andrei Zinovyev,et al.  Systems biology of Ewing sarcoma: a network model of EWS-FLI1 effect on proliferation and apoptosis , 2013, Nucleic acids research.

[17]  V. Notario,et al.  The dual inhibitory effect of thiostrepton on FoxM1 and EWS/FLI1 provides a novel therapeutic option for Ewing’s sarcoma , 2013, International journal of oncology.

[18]  J. Alonso,et al.  Lysyl Oxidase Is Downregulated by the EWS/FLI1 Oncoprotein and Its Propeptide Domain Displays Tumor Supressor Activities in Ewing Sarcoma Cells , 2013, PloS one.

[19]  K. Ross,et al.  The Biology of Ewing Sarcoma , 2013, ISRN oncology.

[20]  R. Bell,et al.  Mechanism and relevance of EWS/FLI-mediated transcriptional repression in Ewing sarcoma , 2012, Oncogene.

[21]  A. Sandler,et al.  Reversible Adaptive Plasticity: A Mechanism for Neuroblastoma Cell Heterogeneity and Chemo-Resistance , 2012, Front. Oncol..

[22]  P. Sorensen,et al.  The First European Interdisciplinary Ewing Sarcoma Research Summit , 2012, Front. Oncol..

[23]  F. Clavel-Chapelon,et al.  Common variants near TARDBP and EGR2 are associated with susceptibility to Ewing sarcoma , 2012, Nature Genetics.

[24]  H. Spaink,et al.  Automated Whole Animal Bio-Imaging Assay for Human Cancer Dissemination , 2012, PloS one.

[25]  M. Ladanyi,et al.  Molecular pathogenesis of Ewing sarcoma: new therapeutic and transcriptional targets. , 2012, Annual review of pathology.

[26]  M. Beckerle,et al.  The EWS/FLI Oncogene Drives Changes in Cellular Morphology, Adhesion, and Migration in Ewing Sarcoma. , 2012, Genes & cancer.

[27]  Qing-Rong Chen,et al.  Identification of an inhibitor of the EWS-FLI1 oncogenic transcription factor by high-throughput screening. , 2011, Journal of the National Cancer Institute.

[28]  J. Hernandez,et al.  SPROUTY-2 and E-cadherin regulate reciprocally and dictate colon cancer cell tumourigenicity , 2010, Oncogene.

[29]  J. Schiffman,et al.  Recent advances in the molecular pathogenesis of Ewing's sarcoma , 2010, Oncogene.

[30]  Alexander Roesch,et al.  A Temporarily Distinct Subpopulation of Slow-Cycling Melanoma Cells Is Required for Continuous Tumor Growth , 2010, Cell.

[31]  G. Werther,et al.  Activation of a prometastatic gene expression program in hypoxic neuroblastoma cells. , 2009, Endocrine-related cancer.

[32]  R. Dummer,et al.  In vivo switching of human melanoma cells between proliferative and invasive states. , 2008, Cancer research.

[33]  B. Chain,et al.  Quantitative imaging assay for NF-κB nuclear translocation in primary human macrophages , 2008, Journal of immunological methods.

[34]  O. Delattre,et al.  Mesenchymal stem cell features of Ewing tumors. , 2007, Cancer cell.

[35]  Todd R Golub,et al.  Signature-Based Small Molecule Screening Identifies Cytosine Arabinoside as an EWS/FLI Modulator in Ewing Sarcoma , 2007, PLoS medicine.

[36]  S. Lessnick,et al.  Expression of EWS-ETS Fusions in NIH3T3 Cells Reveals Significant Differences to Ewing’s Sarcoma , 2006, Cell cycle.

[37]  Quynh-Thu Le,et al.  Lysyl oxidase is essential for hypoxia-induced metastasis , 2006, Nature.

[38]  M. Hervy,et al.  The actin cytoskeleton-associated protein zyxin acts as a tumor suppressor in Ewing tumor cells. , 2005, Experimental cell research.

[39]  O. Delattre,et al.  EWS/FLI-1 Silencing and Gene Profiling of Ewing Cells Reveal Downstream Oncogenic Pathways and a Crucial Role for Repression of Insulin-Like Growth Factor Binding Protein 3 , 2004, Molecular and Cellular Biology.

[40]  B. Cullen,et al.  Inhibition of Human Immunodeficiency Virus Type 1 Replication in Primary Macrophages by Using Tat- or CCR5-Specific Small Interfering RNAs Expressed from a Lentivirus Vector , 2003, Journal of Virology.

[41]  Martin Fussenegger,et al.  Method for generation of homogeneous multicellular tumor spheroids applicable to a wide variety of cell types. , 2003, Biotechnology and bioengineering.

[42]  O. Larsson,et al.  A link between basic fibroblast growth factor (bFGF) and EWS/FLI-1 in Ewing's sarcoma cells , 2000, Oncogene.

[43]  C. Denny,et al.  Ewing sarcoma 11;22 translocation produces a chimeric transcription factor that requires the DNA-binding domain encoded by FLI1 for transformation. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[44]  G. Thomas,et al.  Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours , 1992, Nature.

[45]  M. Israel,et al.  Chromosome translocation in peripheral neuroepithelioma. , 1984, The New England journal of medicine.

[46]  S. Aaronson,et al.  In vitro cultivation of human tumors: establishment of cell lines derived from a series of solid tumors. , 1973, Journal of the National Cancer Institute.

[47]  B. Spengler,et al.  Morphology and growth, tumorigenicity, and cytogenetics of human neuroblastoma cells in continuous culture. , 1973, Cancer research.

[48]  A. Cabrera,et al.  EWING'S SARCOMA. , 1964, Surgery, gynecology & obstetrics.

[49]  M. B. Coventry,et al.  Ewing's sarcoma. A critical analysis of 165 cases. , 1961, The Journal of bone and joint surgery. American volume.

[50]  P. Meltzer,et al.  Molecular and Cellular Pathobiology Cancer Research Hypoxia Modulates EWS-FLI 1 Transcriptional Signature and Enhances the Malignant Properties of Ewing ' s Sarcoma Cells In vitro , 2010 .

[51]  J. Sibarita.  Deconvolution microscopy. , 2005, Advances in biochemical engineering/biotechnology.